Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used?
Degertekin
Bulent
B
Lok
Anna S
AS
D000998:Antiviral Agents / Q000627:therapeutic use; D004279:DNA, Viral / Q000097:blood; D016903:Drug Monitoring / Q000379:methods*; D024882:Drug Resistance, Viral / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006147:Guanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D009154:Mutation / Q000235:genetics; D009705:Nucleosides / Q000627:therapeutic use*; D009711:Nucleotides / Q000627:therapeutic use*; D010641:Phenotype
D000998:Antiviral Agents; D004279:DNA, Viral; D009705:Nucleosides; D009711:Nucleotides; D019259:Lamivudine; C413685:entecavir; D006147:Guanine